<p>Palbociclib is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:</p>

<ul>
	<li>An aromatase inhibitor as initial endocrine-based therapy in postmenopausal women; or</li>
	<li>Fulvestrant in women with disease progression following endocrine therapy.</li>
</ul>